Genmab A/S (GMAB) Financials
NASDAQ:GMABMarket Cap
24.40B
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| 663,570,000 | 850,385,000 | 1,133,041,000 | 1,816,122,000 | 2,365,436,000 | 3,025,137,000 | 5,366,000,000 | 10,111,000,000 | 8,482,000,000 | 14,595,000,000 | |
| -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| 663,570,000 | 850,385,000 | 1,133,041,000 | 1,816,122,000 | 2,365,436,000 | 3,025,137,000 | 5,366,000,000 | 10,111,000,000 | 8,482,000,000 | 14,595,000,000 | |
| 527,576,000 | 505,679,000 | 487,656,000 | 660,876,000 | 874,278,000 | 1,431,159,000 | 2,386,000,000 | 3,137,000,000 | 4,181,000,000 | 5,562,000,000 | |
| -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| 66,741,000 | 79,529,000 | 91,224,000 | 102,413,000 | 146,987,000 | 213,695,000 | 342,000,000 | 661,000,000 | -- | -- | |
| 66,741,000 | 79,529,000 | 91,224,000 | 102,413,000 | 146,987,000 | 213,695,000 | 342,000,000 | 661,000,000 | 1,283,000,000 | 2,676,000,000 | |
| 594,317,000 | 585,208,000 | 402,662,000 | 763,289,000 | 1,021,265,000 | 1,644,854,000 | 2,728,000,000 | 3,798,000,000 | 5,464,000,000 | 8,238,000,000 | |
| 69,253,000 | 265,177,000 | 730,379,000 | 1,052,833,000 | 1,344,171,000 | 1,380,283,000 | 2,638,000,000 | 6,313,000,000 | 3,018,000,000 | 6,357,000,000 | |
| -3,851,000 | 32,169,000 | 27,148,000 | 77,384,000 | -280,451,000 | 231,688,000 | 221,000,000 | -409,000,000 | 965,000,000 | 678,000,000 | |
| 122,599,000 | 313,731,000 | 789,467,000 | 1,171,386,000 | 1,136,273,000 | 1,699,985,000 | 2,897,000,000 | 6,756,000,000 | 3,463,000,000 | 7,043,000,000 | |
| 11,664,000 | 12,331,000 | 31,822,000 | 40,956,000 | 69,751,000 | 87,597,000 | 259,000,000 | 443,000,000 | 445,000,000 | 686,000,000 | |
| 28,613,000 | 38,331,000 | 37,263,000 | 32,583,000 | 41,426,000 | 62,922,000 | 120,000,000 | 184,000,000 | 197,000,000 | 324,000,000 | |
| 3,326,000 | 4,054,000 | 118,000 | 213,000 | 2,802,000 | 417,000 | 7,000,000 | 10,000,000 | 13,000,000 | 21,000,000 | |
| 65,402,000 | 297,346,000 | 757,527,000 | 1,130,217,000 | 1,063,720,000 | 1,611,971,000 | 2,859,000,000 | 5,904,000,000 | 3,983,000,000 | 7,035,000,000 | |
| -4,753,000 | -3,950,000 | -5,986,000 | -56,858,000 | -39,831,000 | 139,830,000 | 693,000,000 | 1,146,000,000 | 975,000,000 | 1,513,000,000 | |
| 112,362,000 | 301,296,000 | 763,513,000 | 1,187,075,000 | 1,103,551,000 | 1,472,141,000 | 2,166,000,000 | 4,758,000,000 | 3,008,000,000 | 5,522,000,000 | |
| 0.22 | 0.54 | 1.31 | 1.98 | 1.81 | 2.4 | 3.44 | 7.3 | 4.6 | 8.45 | |
| 0.22 | 0.53 | 1.26 | 1.92 | 1.78 | 2.37 | 3.4 | 7.22 | 4.55 | 8.37 | |
| 509,770,000 | 563,150,000 | 585,210,000 | 598,760,000 | 608,340,000 | 612,680,000 | 629,628,130 | 651,790,060 | 653,956,370 | 653,873,010 | |
| 519,100,000 | 572,510,000 | 607,740,000 | 617,660,000 | 620,940,000 | 620,450,000 | 636,368,430 | 658,858,750 | 660,457,510 | 660,096,040 | |
| 594,317,000 | 585,208,000 | 402,662,000 | 763,289,000 | 1,021,265,000 | 1,644,854,000 | 2,728,000,000 | 3,798,000,000 | 5,464,000,000 | 8,238,000,000 | |
| -- | -- | -176,218,000 | -- | -- | -- | -- | -- | -- | -- |
Key Facts
Industry
Biotechnology
Sector
Healthcare
Headquarters
Copenhagen, , DK
Website
CEO
Dr. Jan G.J. van de Winkel Ph.D.
Employees
2015
About the Company
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.